Epic Research Update : Biocon

Biocon, Asia’s premier biotechnology company, has introduced CANMAb (150 mg/ 440 mg), a biosimilar trastuzumab for the treatment of HER2-positive metastatic breast cancer in India.

For more information call- 0731-6642300 or Visit-http://goo.gl/g55v85

Posted in: Indian Market Tips